

Edwards & Angell LLP

101 Federal Street Boston, MA 02110 617.439.4144 fax 617.439.4170

FACSIMILE TRANSMITTAL COVER SHEET

DATE: **June 2, 2003**

TO: **Examiner Cybille Delacroix-MUIRHEID**

FAX NO.: 703 746-5033

FROM: **Dianne M. Rees, Ph.D.**

DIRECT FAX NO: (888) 325-9702

Telephone No.: **(617) 951-3351**

APPLICATION NO. 09/864,857

Filing Date: May 23, 2001

Our Reference No.: 55950 (45579)

No. of pages 6

**MESSAGE: PLEASE SEE ATTACHED COPY OF AMENDMENT AND
RELATED PAPERS PREVIOUSLY FILED FOR THE ABOVE-
IDENTIFIED APPLICATION.**

Should there be any problem with this transmission, please contact Helen Murray Tarbi at (617) 517-5514.

NOTICE

The message and/or information which accompanies this facsimile cover sheet is intended for the addressee named above only. If you are not the intended recipient, please contact the sender by collect telephone at the number indicated. You will be advised regarding the disposition of what you have received. The misdelivery of the message and/or information which accompanies this facsimile cover sheet is not intended to be and shall not constitute a disclosure of trade secrets, of attorney work product or of an attorney-client communication. No waiver of any privilege is intended. Thank you for your attention to this matter.

BOS2 JJ7259.1

PFC/DMR
55950
45579



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/864,857	05/23/2001	Claus Sindgroen	55950 (45579)	2018

7590

01/30/2002

Dike, Bronstein, Roberts & Cushman
Intellectual Property Patent Practice
EDWARDS & ANGELL, LLP
130 Water Street
Boston, MA 02109



EXAMINER

DELACROIX MUTRIE, CYBILLE

ART UNIT PAPER NUMBER

1614

DATE MAILED: 01/30/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

COPY

Amendment

Edwards & Angell LLP

Dike, Bronstein, Roberts & Cushman

101 Federal St. Boston, MA 02110

Date Rec'd 2/7/02

Docketed For Apr 30 - Jul 30, 2002

By KRD

Approved _____

Office Action Summary	Application No. 09/864,857		Applicant(s) SUNDGREEN ET AL.	
	Examiner Cybille Delacroix-Mulrhead		Art Unit 1614	

- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☐ Responsive to communication(s) filed on ____.

2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) 1-75 is/are pending in the application.

4a) Of the above claim(s) ____ is/are withdrawn from consideration.

5) ☐ Claim(s) ____ is/are allowed.

6) ☒ Claim(s) 1-5, 70, 72, 74 and 75 is/are rejected.

7) ☒ Claim(s) 6-69, 71 and 73 is/are objected to.

8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.

15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). ____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____	6) <input type="checkbox"/> Other: _____

Application/Control Number: 09/864,857
Art Unit: 1614
Applicant: SUNDGREEN et al.

Page 2

DETAILED ACTION

Claims 1-75 are presented for prosecution on the merits.

Priority

1. If applicant desires priority under 35 U.S.C. 119(e) based upon a previously filed copending application, specific reference to the earlier filed application must be made in the instant application.
2. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

Applicant's Information Disclosure Statement received August 27, 2001 has been considered. Please refer to Applicant's copy of the 1449 submitted herewith.

Specification

3. The abstract of the disclosure is objected to because the abstract is not present in a single paragraph. Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a **single paragraph** on a separate sheet within the range of 50 to 250 words. It is important that the abstract not exceed 250 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

Application/Control Number: 09/864,857

Page 3

Art Unit: 1614

Applicant: SUNDGREEN et al.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

Correction is required. See MPEP § 608.01(b).

4. The following guidelines illustrate the preferred layout and content for patent applications. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

The following order or arrangement is preferred in framing the specification and, except for the reference to "Microfiche Appendix" and the drawings, each of the lettered items should appear in upper case, without underlining or bold type, as section headings. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) Title of the Invention.
- (b) Cross-References to Related Applications.
- (c) Statement Regarding Federally Sponsored Research or Development.
- (d) Reference to a "Microfiche Appendix" (see 37 CFR 1.96).
- (e) Background of the Invention.
 - 1. Field of the Invention.
 - 2. Description of the Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (f) Brief Summary of the Invention.
- (g) **Brief Description of the Several Views of the Drawing(s).**
- (h) Detailed Description of the Invention.
- (i) Claim or Claims (commencing on a separate sheet).
- (j) Abstract of the Disclosure (commencing on a separate sheet).
- (k) Drawings.
- (l) Sequence Listing (see 37 CFR 1.821-1.825).

PLEASE NOTE: A section entitled "A Brief Description of the Drawings" is required.

Claim Objections

Application/Control Number: 09/864,857

Page 4

Art Unit: 1614

Applicant: SUNDGREEN et al.

5. Claims 6-69, 71, 73 are objected to under 37 CFR 1.75© as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits.

6. Claim 2 is objected to because of the following informalities: in claim 2, the phrase "selected from the group consisting of....or" is improper Markush terminology. The phrase should read --selected from the group consisting of....and--. Please see MPEP 2173.05(h). Appropriate correction is required.

Claim Rejections - 35 USC § 112

7. Claims 70, 72, 74, 75 provide for the use of desglymidodrine, but, since the claims do not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 70, 72, 74, 75 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

For purposes of this office action the claims will be interpreted as method of making pharmaceutical compositions containing desglymidodrine.

Application/Control Number: 09/864,857

Page 5

Art Unit: 1614

Applicant: SUNDGREEN et al.

8. Claims 4-5, 75 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

9. Claim 4 recites the limitation "the therapeutically active enantiomeric form of desglymidodrine is (-)-alpha-(aminomethyl)-2,5-dimethoxy-benzenemethanol (-ST 1059)" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim.

10. Regarding claims 5 and 75, the phrases "such as" and "e.g." render the claim indefinite because it is unclear whether the limitations following the phrases are part of the claimed invention. See MPEP § 2173.05(d).

11. Claim 5 recites the limitation "the therapeutically active enantiomeric form" in line 3. There is insufficient antecedent basis for this limitation in the claim. There is no antecedent basis for this limitation in claim 1.

Claim Rejections - 35 USC § 102

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

13. Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Luzi et al. AN 1999-13923 (abstract only).

Luzi et al. disclose studying the hypertensive effects of desglymidodrine or ST-1059 in rats.

Luzi et al. teach administering pharmaceutical compositions of racemic mixtures of ST-1059 or

Application/Control Number: 09/864,857

Page 6

Art Unit: 1614

Applicant: SUNDGREEN et al.

the (+) or (-) enantiomeric form of ST-1059. The results show that the (-) enantiomeric form displayed the hypertensive effect. Please see the abstract submitted herewith.

14. Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 11139968 ('968) abstract only.

JP '968 discloses antihypertensive transdermal preparations in the form of tapes, wherein the preparations contain the active ingredient 2-amino-1-(2,5-dimethoxyphenyl)ethanol (desglymidodrine). Please see the abstract submitted herewith.

Claims 2-5 are anticipated by JP '968 because the transdermal preparations would inherently contain any one of the claimed enantiomeric forms.

15. Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Kontani et al. (Abstract only).

Kontani et al. study the effects of alpha1 adrenergic agonists on an experimental urinary incontinence model in anesthetized rabbits by intravenous administration of a composition containing ST-1059 (desglymidodrine). Please see the abstract submitted herewith.

Claims 2-5 are anticipated by Kontani et al. because the composition would inherently contain any one of the claimed enantiomeric forms.

Claim Rejections - 35 USC § 103

16. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

Application/Control Number: 09/864,857

Page 7

Art Unit: 1614

Applicant: SUNDGREEN et al.

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

17. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

18. Claims 70, 72, 74, 75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Luzi et al., supra or JP '968, supra or Kontani et al., supra.

Luzi et al., JP '968 or Kontani et al. as applied above.

Said references do not specifically disclose methods of making the disclosed compositions; however, it would have been obvious to one of ordinary skill in the art to make the pharmaceutical compositions disclosed by Luzi, JP '968 or Kontani using any method which is

Application/Control Number: 09/864,857

Page 8

Art Unit: 1614

Applicant: SUNDGREEN et al.

well known in the pharmaceutical art. In other words, methods of making pharmaceutical compositions is obvious and well within the capability of the skilled artisan.

Concerning claims 70, 72, 74, 75, which are being examined as a method for preparing a pharmaceutical composition for the treatment of "septic shock" (claim 70); "a condition responsive to alpha1 receptor stimulation" (claim 72); "syncope" (claim 74); and "urinary incontinence" (claim 75), the Examiner respectfully submits that the ultimate intended use of the pharmaceutical composition is not germane to the issue of patentability of the method of making claim. Please refer to MPEP 2111.02, page 2100-46, where it is stated,

"In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. *In re Casey*, 370 F.2d 576, 152 USPQ 235 (CCPA 1967); *In re Otto*, 312 F.2d 937, 938, 136 USPQ 458, 459 (CCPA 1963) (The claims were directed to a core member for hair curlers and a process of making a core member for hair curlers. Court held that the intended use of hair curling was of no significance to the structure and process of making.)".

In the instant case, the Examiner respectfully submits that the intended use of treating the conditions in claims 70, 72, 74 and 75 is of no significance to the process of preparing the pharmaceutical compositions.

Conclusion

Claims 1-5, 70, 72, 74, 75 are rejected.

Claims 6-69, 71, 73 are objected to.

Application/Control Number: 09/864,857
Art Unit: 1614
Applicant: SUNDGREEN et al.

Page 9

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cybille Delacroix-Muirheid whose telephone number is (703) 306-3227. The examiner can normally be reached on Tue-Fri from 8:30 to 6:00. The examiner can also be reached on alternate Mondays.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Scidcl, can be reached on (703) 308-4725. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

CDM

Jan: 27, 2002


Cybille Delacroix-Muirheid
Patent Examiner Group 1600



TECH CENTER 1600/2900

 RECEIVED
 AUG 30 2001
 Sheet of 1

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

DOCKET NO.: 55950

SERIAL NO.: 09/864,857

APPLICANT(S): C. Sundgreen et al.

FILING DATE: May 23, 2001

GROUP NO.: 1614

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
com	AA	5,610,174	03/11/97	Craig et al.	514	401	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

com	AB	V. Grobecker et al., <i>International Angiology</i> , 12(2):19-124 (1993).					
com	AC	H. Grobecker et al., <i>Arzneim.-Forsch</i> , 37(4):447-450 (1987).					

Examiner:

Cybil Delaney-Stunheid

Date:

1/27/02

Notice of References Cited	Application/Control No. 09/864,857	Applicant(s)/Patent Under Reexamination SUNDGREEN ET AL.	
	Examiner Cybille Delacroix-Muirheld	Art Unit 1614	Page 1 of 1


U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	LUZI et al., AN1999-13923 DRUGU, Eur. J. Pharm. Sci. (6, Suppl. 1, S56, 1998) abstract only.
	V	CAPLUS DN 131:23512, Sekawa et al., JP 11139968, 1999/05/25, abstract only.
	W	CAPLUS DN 117:576, Kontani et al., Jpn. J. Pharmacol. (1992), 58(4), 339-48. abstract only.
	X	 1/27/02

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Attachment for PTO-948 (Rev. 03/01, or earlier)
6/18/01**

The below text replaces the pre-printed text under the heading, "Information on How to Effect Drawing Changes," on the back of the PTO-948 (Rev. 03/01, or earlier) form.

INFORMATION ON HOW TO EFFECT DRAWING CHANGES

1. Correction of Informalities -- 37 CFR 1.85

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the Notice of Allowability. Extensions of time may **NOT** be obtained under the provisions of 37 CFR 1.136(a) or (b) for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

2. Corrections other than Informalities Noted by Draftsperson on form PTO-948.

All changes to the drawings, other than informalities noted by the Draftsperson, **MUST** be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings **MUST** be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

Timing of Corrections

Applicant is required to submit the drawing corrections within the time period set in the attached Office communication. See 37 CFR 1.85(a).

Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.

06/01/01

PFC/DMR
55950 (45579)

COPY

R-1

Mailing Date: July 30, 2002

Client: 45579

Inventors: SUNDGREEN, et al.

Serial No.: 09/864,857


Filing Date: MAY 23, 2001

Attorney/Sec: PFC/DMR/NT

Docket No.: 55950

Patent No.: N/A

Grant Date: N/A



The dating stamp of the Patent and Trademark Office hereon will be taken as the date of filing of:

- AMENDMENT TRANSMITTAL INCLUDING PETITION FOR 3-MONTH EXTENSION OF TIME;
- AMENDMENT AND RESPONSE TO NON-FINAL OFFICE ACTION MAILED JANUARY 30, 2002
- CHECK FOR \$920.00; AND RETURN RECEIPT POSTCARD

Due Date: JULY 30, 2002



EDWARDS & ANGELL, LLP
COUNSELLORS AT LAW
since 1894
101 Federal Street
Boston, MA 02110



www.fleet.com

2-36/112

No.

708551

CHECK DATE

CHECK NO.

July 30, 2002

708551

CHECK AMOUNT

***920.00

NINE HUNDRED TWENTY AND 00/100 DOLLARS

COPY

PAY TO
ORDER
OF

Commissioner of Patents & Trademarks

Boston Main Account
Two Signatures Required For Amounts Exceeding \$2000.00
VOID IF 180 DAYS OR OLDER

THIS DOCUMENT CONTAINS HEAT SENSITIVE INK. TOUCH OR PRESS HERE. RED IMAGE DISAPPEARS WITH HEAT.

⑈ 708551 ⑈ ⑈ 011200365⑈ 93550 27633 ⑈

EDWARDS & ANGELL, LLP
COUNSELLORS AT LAW

Boston Main Account

NUMBER

708551

COMMISSION Commissioner of Patents & Trademarks

Invoice No.	Invoice Date	Description	Invoice Amount	Discount	Payment Amount
45579.55950D	07/30/2002	for PTO code 117	\$920.00	\$0.00	\$920.00